The cleavage kinetics of hydrazide derivatives of isoniazid by HPLC-UV/DAD and its impact on activity against Mycobacterium tuberculosis

被引:1
作者
Gouvea, Marcos Martins [1 ,3 ]
de Carvalho, Renata Correa [1 ]
Castelo-Branco, Frederico Silva [3 ]
Boechat, Nubia [3 ]
Netto, Annibal Duarte Pereira [1 ,2 ]
Marques, Flavia Ferreira de Carvalho [1 ]
机构
[1] Univ Fed Fluminense, Inst Quim, Programa Posgrad Quim, Outeiro Sao Joao Batista,S-N, BR-24020141 Niteroi, RJ, Brazil
[2] Univ Fed Estado Rio Janeiro, Programa Posgrad Alimentos & Nutr, Ave Pasteur 296, BR-22290240 Rio De Janeiro, RJ, Brazil
[3] Fundacao Oswaldo Cruz, Lab Sintese Farmacos, Inst Tecnol Farmacos Farmanguinhos Fiocruz, LASFAR, BR-21041250 Rio De Janeiro, RJ, Brazil
来源
JOURNAL OF CHROMATOGRAPHY B-ANALYTICAL TECHNOLOGIES IN THE BIOMEDICAL AND LIFE SCIENCES | 2022年 / 1188卷
关键词
Tuberculosis; Isoniazid; Isatin; Cleavage; Kinetics; Liquid Chromatography; SERIES;
D O I
10.1016/j.jchromb.2021.123080
中图分类号
Q5 [生物化学];
学科分类号
071010 ; 081704 ;
摘要
Isoniazid is a first-line drug for the treatment of tuberculosis, a bacterial disease caused by Mycobacterium tuberculosis. Its terminal amino group is highly reactive, leading to significant metabolic deactivation, drug interactions and hepatotoxicity. It is speculated that the activity of isoniazid derivatives is, in part, related to the cleavage of the protecting group. Therefore, this study aimed to evaluate the cleavage characteristics of previously developed isoniazid derivatives through kinetic studies by high-performance liquid chromatography with ultraviolet-diode array detectio to establish a comparison between the rates of the process and the respective activities against M. tuberculosis. Chromatographic separations were performed on an XDB C18 column coupled to an XDB C18 precolumn. The mobile phase consisted of ultrapure water and acetonitrile in gradient mode. The flow rate was 1.0 mL/min, the injection volume was 20 mu L, and the detection wavelengths were 230 nm (derivatives and isatins) and 270 nm (isoniazid). Incubation of derivatives was carried out for 5 days in 10 mmol/L phosphate buffer solution (pH 3.0, 7.4, 8.0) or in fetal bovine serum at 37 degrees C. The incubation reduced the concentration of the derivatives and led to the formation of isoniazid in a first-order kinetic reaction. Isoniazid formation was logarithmically correlated with the minimum inhibitory concentration of the derivatives. The results showed that higher cleavage rates are associated with greater activities against M. tuberculosis, providing important information for the development of future generations of isoniazid derivatives and for screening drug candidates for the treatment of tuberculosis.
引用
收藏
页数:7
相关论文
共 20 条
[1]   Antituberculosis drugs: Drug interactions, adverse effects, and use in special situations. Part 1: First-line drugs [J].
Arbex, Marcos Abdo ;
Lima Varella, Marilia de Castro ;
de Siqueira, Helio Ribeiro ;
Fiuza de Mello, Fernando Augusto .
JORNAL BRASILEIRO DE PNEUMOLOGIA, 2010, 36 (05) :626-640
[2]   The thick waxy coat of mycobacteria, a protective layer against antibiotics and the host's immune system [J].
Batt, Sarah M. ;
Minnikin, David E. ;
Besra, Gurdyal S. .
BIOCHEMICAL JOURNAL, 2020, 477 (10) :1983-2006
[3]   Isioniazid-resistance conferring mutations in Mycobacterium tuberculosis KatG: Catalase, peroxidase, and INH-NADH adduct formation activities [J].
Cade, Christine E. ;
Dlouhy, Adrienne C. ;
Medzihradszky, Katalin F. ;
Salas-Castillo, Saida Patricia ;
Ghiladi, Reza A. .
PROTEIN SCIENCE, 2010, 19 (03) :458-474
[4]   New hydrazides derivatives of isoniazid against Mycobacterium tuberculosis: Higher potency and lower hepatocytotoxicity [J].
Castelo-Branco, Frederico Silva ;
de Lima, Evanoel Crizanto ;
de Oliveira Domingos, Jorge Luiz ;
Pinto, Angelo C. ;
Lourenco, Maria Cristina S. ;
Gomes, Karen Machado ;
Costa-Lima, Mariana Marques ;
Araujo-Lima, Carlos Fernando ;
Fortes Aiub, Claudia Alessandra ;
Felzenszwalb, Israel ;
Costa, Thadeu Estevam M. M. ;
Penido, Carmen ;
Henriques, Maria G. ;
Boechat, Nubia .
EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY, 2018, 146 :529-540
[5]   World Health Organization cardiovascular disease risk charts: revised models to estimate risk in 21 global regions [J].
Di Angelantonio, Emanuele ;
Kaptoge, Stephen ;
Pennells, Lisa ;
De Bacquer, Dirk ;
Cooney, Marie Therese ;
Kavousi, Maryam ;
Stevens, Gretchen ;
Riley, Leanne ;
Savin, Stefan ;
Altay, Servet ;
Amouyel, Philippe ;
Assmann, Gerd ;
Bell, Steven ;
Ben-Shlomo, Yoav ;
Berkman, Lisa ;
Beulens, Joline W. ;
Bjorkelund, Cecilia ;
Blaha, Michael J. ;
Blazer, Dan G. ;
Bolton, Thomas ;
Bonita, Ruth ;
Brenner, Beaglehole Hermann ;
Brunner, Eric J. ;
Casiglia, Edoardo ;
Chamnan, Parinya ;
Choi, Yeun-Hyang ;
Chowdhury, Rajiv ;
Coady, Sean ;
Crespo, Carlos J. ;
Cushman, Mary ;
Dagenais, Gilles R. ;
D'Agostino, Ralph B. ;
Daimon, Makoto ;
Davidson, Karina W. ;
Engstrom, Gunnar ;
Fang, Xianghua ;
Ford, Ian ;
Gallacher, John ;
Gansevoort, Ron T. ;
Gaziano, Thomas Andrew ;
Giampaoli, Simona ;
Grandits, Greg ;
Grimsgaard, Sameline ;
Grobbee, Diederick E. ;
Gudnason, Vilmundur ;
Guo, Qi ;
Humphries, Steve ;
Iso, Hiroyasu ;
Jukema, J. Wouter ;
Kauhanen, Jussi .
LANCET GLOBAL HEALTH, 2019, 7 (10) :E1332-E1345
[6]  
ELLARD GA, 1976, CLIN PHARMACOL THER, V19, P610
[7]   Rapid, low-technology MIC determination with clinical Mycobacterium tuberculosis isolates by using the microplate Alamar Blue assay [J].
Franzblau, SG ;
Witzig, RS ;
McLaughlin, JC ;
Torres, P ;
Madico, G ;
Hernandez, A ;
Degnan, MT ;
Cook, MB ;
Quenzer, VK ;
Ferguson, RM ;
Gilman, RH .
JOURNAL OF CLINICAL MICROBIOLOGY, 1998, 36 (02) :362-366
[8]   Tuberculosis [J].
Frieden, TR ;
Sterling, TR ;
Munsiff, SS ;
Watt, CJ ;
Dye, C .
LANCET, 2003, 362 (9387) :887-899
[9]   A new modification of anti-tubercular active molecules [J].
Imramovsky, Ales ;
Polanc, Slovenko ;
Vinsova, Jarmila ;
Kocevar, Marijan ;
Jampilek, Josef ;
Reckova, Zuzana ;
Kaustova, Jarmila .
BIOORGANIC & MEDICINAL CHEMISTRY, 2007, 15 (07) :2551-2559
[10]   Discovery and Structure Optimization of a Series of Isatin Derivatives as Mycobacterium tuberculosis Chorismate Mutase Inhibitors [J].
Jeankumar, Variam U. ;
Alokam, Reshma ;
Sridevi, Jonnalagadda P. ;
Suryadevara, Priyanka ;
Matikonda, Siddharth S. ;
Peddi, Santosh ;
Sahithi, Seedarala ;
Alvala, Mallika ;
Yogeeswari, Perumal ;
Sriram, Dharmarajan .
CHEMICAL BIOLOGY & DRUG DESIGN, 2014, 83 (04) :498-506